Dana-Farber Cancer Institute shared a post on LinkedIn:
“For years, researchers have explored BAX protein’s role in cell death, a promising target for cancer therapy. New findings by Dana-Farber offer a starting point for drugs that inhibit BAX through a covalent mechanism.
‘BAX has been a focus of my lab for nearly 20 years,’ says Loren Walensky, MD, PhD, who began studying the protein as a postdoctoral fellow in the early 2000s. ‘Its enormous potential as a therapeutic target – if you activate it, you can cause malignant cells to die; if you shut it down, you can prevent healthy cells from dying – led us to explore its mechanism of activation and de-activation.’
Learn more here.”